Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Offidani

Showing results (1-10 of 149) with videos related to

Pageof 15
Sort By:
Future Oncology (London, England)|November 2, 2017
A review discussing elotuzumab and its use in the second-line plus treatment of multiple myelomaMassimo Offidani, Laura Corvatta
Pharmaceuticals (Basel, Switzerland)|November 20, 2020
Introduction to "Immunotherapies for Multiple Myeloma"Massimo Offidani, Maria Teresa Petrucci
British Journal of Haematology|December 21, 2022
Maintenance therapy in multiple myeloma: Two is not always better than oneMassimo Offidani, Sonia Morè, Laura Corvatta
Expert Opinion on Pharmacotherapy|December 22, 2017
Triplet vs. doublet drug regimens for managing multiple myelomaMassimo Offidani, Laura Corvatta, Silvia Gentili
Drug Design, Development and Therapy|June 9, 2021
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and SafetyMassimo Offidani, Laura Corvatta, Sonia Morè, et al.
Journal of Experimental Pharmacology|March 17, 2021
Novel Experimental Drugs for Treatment of Multiple MyelomaMassimo Offidani, Laura Corvatta, Sonia Morè, et al.
Expert Review of Anticancer Therapy|November 22, 2015
Oral ixazomib maintenance therapy in multiple myelomaMassimo Offidani, Laura Corvatta, Silvia Gentili, et al.
Leukemia & Lymphoma|June 3, 2014
Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial dataAntonio Palumbo, Massimo Offidani, Francesca Patriarca, et al.
Cancers|June 10, 2023
Belantamab Mafodotin: From Clinical Trials Data to Real-Life ExperiencesSonia Morè, Massimo Offidani, Laura Corvatta, et al.
Cancers|May 16, 2023
Current Main Topics in Multiple MyelomaSonia Morè, Laura Corvatta, Valentina Maria Manieri, et al.
Pageof 15

Showing results (1-10 of 149) with videos related to

Sort By:
Pageof 15
Future Oncology (London, England)|November 2, 2017
A review discussing elotuzumab and its use in the second-line plus treatment of multiple myelomaMassimo Offidani, Laura Corvatta
Pharmaceuticals (Basel, Switzerland)|November 20, 2020
Introduction to "Immunotherapies for Multiple Myeloma"Massimo Offidani, Maria Teresa Petrucci
British Journal of Haematology|December 21, 2022
Maintenance therapy in multiple myeloma: Two is not always better than oneMassimo Offidani, Sonia Morè, Laura Corvatta
Expert Opinion on Pharmacotherapy|December 22, 2017
Triplet vs. doublet drug regimens for managing multiple myelomaMassimo Offidani, Laura Corvatta, Silvia Gentili
Drug Design, Development and Therapy|June 9, 2021
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and SafetyMassimo Offidani, Laura Corvatta, Sonia Morè, et al.
Journal of Experimental Pharmacology|March 17, 2021
Novel Experimental Drugs for Treatment of Multiple MyelomaMassimo Offidani, Laura Corvatta, Sonia Morè, et al.
Expert Review of Anticancer Therapy|November 22, 2015
Oral ixazomib maintenance therapy in multiple myelomaMassimo Offidani, Laura Corvatta, Silvia Gentili, et al.
Leukemia & Lymphoma|June 3, 2014
Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial dataAntonio Palumbo, Massimo Offidani, Francesca Patriarca, et al.
Cancers|June 10, 2023
Belantamab Mafodotin: From Clinical Trials Data to Real-Life ExperiencesSonia Morè, Massimo Offidani, Laura Corvatta, et al.
Cancers|May 16, 2023
Current Main Topics in Multiple MyelomaSonia Morè, Laura Corvatta, Valentina Maria Manieri, et al.
Pageof 15